An observational study in Acute Myeloid Leukemia, Adult, sponsored by University of Freiburg. Completed at 1 site in Germany. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-05-08.
Sponsored by University of Freiburg · Observational
In this study, we aim to investigate the expression of CKLF like MARVEL transmembrane domain containing 6 (CMTM6) in leukemia cells of patients with acute myeloid leukemia (AML). We will use peripheral blood samples and assess CMTM6 expression by flow cytometry and Western Blot.
5,441 studies on the registry are indexed under Leukemia; 636 are open to participants now.
This study's enrollment of 150 is above the median of 120 across 744 observational studies indexed under Leukemia.
Browse Leukemia studies →University of Freiburg is the lead sponsor of 27 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with AML at primary diagnosis ≥ 18 years of age
or
healthy probands ≥ 18 years of age
Exclusion Criteria:
Peripheral blood will be taken at the timepoint of primary diagnosis and analyzed for CMTM6 expression and T cell activation
Peripheral blood will be taken analyzed for CMTM6 expression and T cell activation
CMTM6 expression (FC)
CMTM6 expression on blasts/monocytes will be measured by flow cytometry
Time frame: At primary diagnosis
T cell activation (FC)
T cell activation and cytokine production will be measured by flow cytometry
Time frame: At primary diagnosis
CMTM6 expression (WB)
CMTM6 expression on blasts/monocytes will be measured by Western blot
Time frame: At primary diagnosis
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Freiburg